Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Literature DB >> 30931524

Enduring efficacy and tolerability of daratumumab in combination with lenalidomide and dexamethasone in patients with relapsed or relapsed/refractory multiple myeloma (GEN503): final results of an open-label, phase 1/2 study.

Abstract

Entities: Chemical Disease Species

Keywords: daratumumab; monoclonal antibody; multiple myeloma; plasma cell disorders; relapsed/refractory multiple myeloma

Year: 2019 PMID： 30931524 DOI： 10.1111/bjh.15879

Source DB: PubMed Journal: Br J Haematol ISSN： 0007-1048 Impact factor: 6.998

× No keyword cloud information.

5 in total

Authors: Bita Fakhri; Mark A Fiala; Nina Shah; Ravi Vij; Tanya M Wildes
Journal: Cancer Date: 2019-11-13 Impact factor: 6.860

Authors: Margaret G Lamb; Hemalatha G Rangarajan; Brian P Tullius; Dean A Lee
Journal: Stem Cell Res Ther Date: 2021-03-25 Impact factor: 6.832

Authors: Jesus F San-Miguel; Hermann Einsele; Philippe Moreau
Journal: Adv Ther Date: 2016-09-27 Impact factor: 3.845

Authors: Nadine Abdallah; Shaji K Kumar
Journal: Ther Adv Hematol Date: 2019-12-23

Authors: Ilse P G Verpoorte-Botden; Monique C Minnema; Reinier A P Raymakers
Journal: Blood Cancer J Date: 2020-11-04 Impact factor: 11.037

5 in total